Clinical Trial Update: A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD） [Phase 3]

View source ↗

Summary

Phase 3 trial update for TAS-205 in Duchenne muscular dystrophy has completed for REACH-DMD study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• TAS-205 (TAS-205)

Snippet

Sponsor: Taiho Pharmaceutical Co., Ltd. | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: COMPLETED